Impact of Adapted Mirror Therapy on Individuals With Hemiparesis of the Upper Limb Following a Stroke

Hemiparesis Clinical Trial

Official title:

Impact of Adapted Mirror Therapy on Individuals With Hemiparesis of the Upper Limb Following a Stroke: A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06301659
• Other study ID #: Jingxiang-Jiu
• Status: Completed
• Phase: N/A
• Start date: August 1, 2022
• Est. completion date: August 31, 2023

Study information

• Verified date: June 2024
• Source: Ahmadu Bello University Teaching Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with upper limb hemiplegia after stroke, who were admitted in the Department of Rehabilitation Medicine, were enrolled. The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy. Additionally, the patients in the experimental group were given modified mirror therapy. On day 1 and day 30, patients' Upper Limb function were compared.

Description:

Upper limb hemiparesis is a motor and sensory disorder that occurs after stroke, with an incidence rate of up to 55% to 75%. This was a Randomized controlled trial. Patients with upper limb hemiplegia after stroke, who were admitted in the Department of Rehabilitation Medicine, were enrolled. The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy. Additionally, the patients in the experimental group were given modified mirror therapy. On day 1 and day 30, patients' Upper Limb function were compared.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 116
• Est. completion date: August 31, 2023
• Est. primary completion date: July 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 70 Years

Eligibility

Inclusion Criteria:

• Meeting the diagnostic criteria of stroke.

• The first-onset stroke.

• Presenting with unilateral upper limb dysfunction, within Brunnstrom stage ? to ? on the affected side, and Ash-worth score =2.

• No obvious cognitive impairment, with Mini-Mental State Examination (MMSE) score >21 points.

• National Institutes of Health Stroke Scale (NIHSS) score >4 points.

• Stable vital signs, no severe diseases such as cancer, liver or kidney disorders.

• Aged 35-70 years.

• Courses of diseases 2-6 weeks.

Exclusion Criteria:

• Presence of aphasia, apraxia, or hemispatial neglect.

• Presence of hearing, vision, or comprehension impairments that hinder diagnosis and treatment.

• Complicate with traumas, fractures, or other progressive neuro-muscular system diseases.

• Severe spasticity in the upper limbs.

• Severe bone, joint, or muscle deformities or lesions.

• History of mental illness.

Related Conditions & MeSH terms

• Hemiparesis
• Paresis

Intervention

Behavioral:
• routine rehabilitation therapy
The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
• Modified mirror therapy
The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).

Locations

Country	Name	City	State
China	Affiated Hos.	Huabei

Sponsors (1)

Lead Sponsor	Collaborator
Ahmadu Bello University Teaching Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fugl-Meyer Assessment-Upper Extremity	The Fugl-Meyer Assessment-Upper Extremity was used to evaluate the patient's upper limb function and motor control. It included the assessment of movements in the shoulder, elbow joint, wrist, and fingers. During the assessment, the assessor observed and recorded the patient's abilities and limitations in specific actions. Based on the patient's performance in each sub-item, the assessor assigned a score using a 0-2 scale, a score of 0 indicating inability to perform, 1 indicating partial ability, and 2 indicating full ability. Finally, the scores for each sub-item were summed up to obtain an overall upper limb function score of 0-66, with scores positively correlated with the upper limb function.	day 1 and day 30
Secondary	coordinated contraction rate-Surface electromyography	The surface electromyography (sEMG) was used to assess the coordinated contraction rates of the biceps brachii on the affected upper limb. The surface electromyography device was used for detection, with the most prominent part of muscle belly of the biceps brachii serving as the monitoring points. During the maximum isometric voluntary contraction (MIVC) state of elbow flexion or extension, two channels were used to separately record the integrated electromyographic values (iEMG) of the biceps brachii, and the antagonists. Measurements were taken three times to obtain the maximum value, and the coordinated contraction rate (CR) during elbow flexion or extension under MIVC conditions was calculated using the formula: CR (%) = Antagonist muscle iEMG / (Agonist muscle iEMG + Antagonist muscle iEMG).	day 1 and day 30
Secondary	Visual Analog Scale	the pain level of the affected shoulder was measured using the Visual Analog Scale (VAS), with 0 indicating no pain and 10 indicating unbearable severe pain. The lower score indicated the lighter pain.	day 1 and day 30
Secondary	Anxiety	The anxiety was assessed using the Generalized Anxiety Disorder-7 (GAD-7), including items related to fear, worry, attention, etc. The total score ranged from 0 to 21, which was positively correlated with potential anxiety. In the previous study, the GAD-7 scale demonstrated a Cronbach's a-coefficient of 0.879. The scores range from 0 to 21. The higher scores mean a worse outcome.	day 1 and day 30
Secondary	Depression	The depression was assessed using the Patient Health Questionnaire-9 (PHQ-9), with aspects including mood swings, optimism, sleep quality, appetite, etc. The total score of PHQ-9 ranged from 0 to 27, which was positively correlated with potential depression. In the previous study, the PHQ-9 scale demonstrated a Cronbach's a-coefficient of 0.913.The scores range from 0 to 27.The higher scores mean a worse outcome.	day 1 and day 30